Humira

Humira Side Effects

For Patients

Humira (adalimumab) is used to treat rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis. It is also used to treat Crohn's disease after other drugs have been tried without successful treatment of symptoms. It is an injectable protein (antibody). Common side effects include redness, itching, pain, or swelling at the injection site.

The recommended dose of Humira for adult patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), or ankylosing spondylitis (AS) is 40 mg administered every other week. Pediatric dosage is determined by the child's weight. Other drugs may interact with Humira. Tell your doctor all prescription and over-the-counter medications and supplements you use. During pregnancy, Humira should be used only when prescribed. It is unknown if this drug passes into breast milk. Similar drugs pass into breast milk. Consult your doctor before breast-feeding.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Humira in Detail - Patient Information: Side Effects

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.

• fever, night sweats, weight loss, tiredness;

• feeling full after eating only a small amount;

• pain in your upper stomach that may spread to your shoulder;

• easy bruising or bleeding, pale skin, feeling light-headed or short of breath, rapid heart rate; or

• nausea, upper stomach pain, itching, loss of appetite, dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes).

Stop using adalimumab and call your doctor at once if you have any of these other serious side effects:

• signs of infection (fever, chills, sore throat, vomiting, diarrhea, flu symptoms);

• shortness of breath with swelling of your ankles or feet;

• confusion, neck stiffness, seizure (convulsions);

• pain or burning when you urinate;

• chest pain, ongoing cough, coughing up mucus or blood;

• numbness or tingly feeling, weakness in your legs;

• red, purple, or scaly skin rash, hair loss, joint or muscle pain, mouth sores;

• joint pain or swelling with fever, swollen glands, muscle aches, vomiting, unusual thoughts or behavior, and/or seizure (convulsions); or

• patchy skin color, red spots, or a butterfly-shaped skin rash over your cheeks and nose (worsens in sunlight).

Less serious side effects may include:

• headache;

• stuffy nose, sinus pain;

• nausea, stomach pain; or

• pain, redness, itching, swelling, or bleeding where you injected the medication.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Humira Overview - Patient Information: Side Effects

SIDE EFFECTS: Redness, itching, pain, or swelling at the injection site may occur. If any of these effects persist or worsen, notify your doctor or pharmacist promptly.

Remember that your doctor has prescribed this medication because he or she has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.

Tell your doctor immediately if any of these unlikely but serious side effects occur: fast/irregular/pounding heartbeat, stomach pain, blood in the stools, mental/mood changes, severe headache, easy bruising or bleeding, dark urine, yellowing eyes and skin, leg pain or swelling, numbness or tingling of the hands or feet, unsteadiness, unexplained muscle weakness, vision changes, extreme fatigue, joint pain, butterfly-shaped rash on the nose and cheeks.

Seek immediate medical attention if any of these rare but very serious side effects occur: seizures, chest pain.

Tell your doctor immediately if you develop signs of infection while using this drug, such as: fever, chills, night sweats, persistent sore throat, trouble breathing, painful or frequent urination, persistent cough, unusual vaginal discharge, white patches in the mouth (oral thrush).

A very serious allergic reaction to this drug is rare. However, seek immediate medical attention if you notice any symptoms of a serious allergic reaction, including: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.

This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist.

In the US -

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

For Healthcare Professionals

Applies to adalimumab: subcutaneous kit

General

The most serious adverse reactions associated with adalimumab (the active ingredient contained in Humira) have been serious infections, neurologic events, and malignancies. The most common adverse reactions have been injection site reactions. In clinical trials, 7% of patients discontinued treatment due to adverse events (vs 4% with placebo).

Other

The incidence of infection was 1 per patient year (vs. 0.9 with placebo). The most common infections were upper respiratory tract infections (17%), bronchitis, and urinary tract infections (8%). The incidence of serious infections was 0.04 per patient year (vs. 0.02 with placebo). Serious infections included pneumonia, septic arthritis, prosthetic and postsurgical infections, erysipelas, cellulitis, diverticulitis, pyelonephritis, tuberculosis (13 cases), and invasive opportunistic infections (6 cases). One fatality due to herpes zoster with secondary streptococcal necrotizing fasciitis was reported during a clinical trial (n=636). A leprosy reaction has been reported following discontinuation of adalimumab (the active ingredient contained in Humira)

Most of the tuberculosis cases occurred within the first 8 months of therapy and included miliary, lymphatic, peritoneal, and pulmonary types. Opportunistic infections were due to histoplasma, aspergillus, and nocardia.

Nervous system

Nervous system side effects have included headache (12%). Confusion, multiple sclerosis, paresthesia, subdural hematoma, and tremor have been reported in less than 5% of patients. A case of hypertrophic pachymeningitis has also been reported. Adalimumab (the active ingredient contained in Humira) and other TNF blockers have been associated with symptoms or evidence suggestive of demyelinating disease. Postmarketing reports have included demyelinating disorders (optic neuritis, Guillain-Barré syndrome) and cerebrovascular accident.

Oncologic

During the controlled portions of adalimumab (the active ingredient contained in Humira) trials in patients with moderately to severely active rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, malignancies (other than lymphoma and non-melanoma skin cancer) were observed at a rate of 0.7 per 100 patient-years among adalimumab-treated patients versus a rate of 0.3 per 100 patient-years among control patients. The median duration of treatment was 5.7 months for adalimumab-treated patients and 5.5 months for control-treated patients.

During the controlled portions of adalimumab rheumatoid arthritis trials, the rate of non-melanoma skin cancers was 0.9 per 100 patient-years among adalimumab-treated patients and 0.2 per 100 patient-years among control patients.

More cases of malignancies have been observed among patients receiving TNF blockers, including adalimumab, compared to controls. Patients with rheumatoid arthritis, particularly those with highly active disease, are at a higher risk for the development of lymphoma.

A meta-analysis has reported that there is dose-dependent increased risk of malignancies in patients with rheumatoid arthritis treated with anti-TNF antibody therapy.

Oncologic side effects have included adenoma, carcinomas (breast, gastrointestinal, skin, urogenital), lymphoma, and melanoma in less than 5% of patients. A case of acute myelogenic leukemia has also been reported. A rare cancer of the white blood cells (known as Hepatosplenic T-Cell Lymphoma or HSTCL), mostly in adolescents and young adults being treated with tumor necrosis factors (TNF) blockers, continues to be reported to FDA.

Immunologic

Immunologic side effects have included development of autoantibodies. Postmarketing reports have included sarcoidosis.

Positive ANA titers were observed at week 24 in 12% of patients (vs 7% with placebo). One patient (0.04%) developed symptoms of new-onset lupus-like syndrome and recovered after discontinuation of adalimumab.

Low-titer antibodies to adalimumab have been observed at least once during treatment in 5% of patients (n=1062). Antibodies developed in 12% of patients on adalimumab monotherapy and in 1% of patients on concurrent methotrexate. During monotherapy, the ACR20 (American College of Rheumatology criteria) response was lower in antibody-positive patients.

A meta-analysis has reported that there is evidence of an increased risk of serious infections in patients with rheumatoid arthritis treated with anti-TNF antibody therapy.

Musculoskeletal

Musculoskeletal side effects have included back pain in 6% of patients; and arthritis, bone disorder, nonspontaneous bone fracture, bone necrosis, joint disorder, muscle cramps, myasthenia, pyogenic arthritis, synovitis, and tendon disorder in less than 5% of patients. A case of severe myalgia has also been reported.

Respiratory

Respiratory side effects have included upper respiratory infection (17%), sinusitis (11%), and flu syndrome (7%). Asthma, bronchospasm, dyspnea, lung disorder, decrease lung function, pleural effusion, pneumonia, and interstitial lung disease including pulmonary fibrosis have been reported in less than 5% of patients. Postmarketing reports have included interstitial lung disease (including pulmonary fibrosis) and pulmonary embolism.

Gastrointestinal

Gastrointestinal side effects have included nausea (9%) and abdominal pain (7%). Cholecystitis, cholelithiasis, esophagitis, gastroenteritis, gastrointestinal disorder, gastrointestinal hemorrhage, hepatic necrosis, and vomiting have been reported in less than 5% of patients. Postmarketing reports have included diverticulitis, large bowel perforations including perforations associated with diverticulitis and appendiceal perforations associated with appendicitis, and pancreatitis.

Metabolic

Metabolic side effects have included hypercholesterolemia (6%), hyperlipidemia (7%), increased alkaline phosphatase (5%), and unspecified abnormal laboratory tests (8%). Dehydration, abnormal healing, ketosis, paraproteinemia, and peripheral edema have been reported in less than 5% of patients.

Genitourinary

Genitourinary side effects have included urinary tract infection (8%) and hematuria (5%). Cystitis, kidney calculus, menstrual disorder and pyelonephritis have been reported in less than 5% of patients.

Local

Local side effects have included injection site pain (12%) and injection site reaction (8%).

Dermatologic

Dermatologic side effects have included rash (12%). Cellulitis, erysipelas, cutaneous vasculitis, and herpes zoster have been reported in less than 5% of patients. There have been postmarketing reports of Stevens Johnson Syndrome, cutaneous vasculitis, erythema multiforme, new or worsening psoriasis (all subtypes including pustular and palmoplantar) and alopecia.

Cardiovascular

Cardiovascular side effects have included hypertension (5%). Arrhythmia, atrial fibrillation, cardiovascular disorder, chest pain, congestive heart failure, coronary artery disorder, heart arrest, hypertensive encephalopathy, myocardial infarct, palpitation, pericardial effusion, pericarditis, syncope, tachycardia, and vascular disorder have been reported in less than 5% of patients. There have been postmarketing reports of systemic vasculitis and deep vein thrombosis.

Cases of worsening congestive heart failure (CHF) and new onset CHF have been reported with TNF blockers, including adalimumab. In clinical studies of another TNF blocker, a higher rate of serious CHF-related adverse events was observed.

Endocrine

Endocrine side effects have included parathyroid disorder in less than 5% of patients.

Hematologic

Hematologic side effects have included agranulocytosis, granulocytopenia, leukopenia, thrombocytopenia, lymphoma-like reaction, pancytopenia, polycythemia, and leg thrombosis in less than 5% of patients. A case of hypertriglyceridemia has also been reported.

Other

Side effects affecting the body as a whole have included fever, infection, extremity pain, pelvic pain, sepsis, surgery, thorax pain, and reactivated tuberculosis in less than 5% of patients.

Accidental injury has been reported in 10% of patients.

Ocular

Ocular side effects have included cataract (<5%).

Hypersensitivity

Hypersensitivity side effects including anaphylaxis and angioneurotic edema have been reported.

Hepatic

Hepatic side effects have included postmarketing reports of liver failure.

 

If you are currently taking prescription medication for your symptoms and are interested in building more health and perhaps getting off your medication by addressing the cause of your health concern, please call the office and let us discuss your options.  I will work with your medical doctor to restore your health and reduce or eliminate the need for medication.

 

Dr. Huntoon has a single mission:

To support as many people as possible in their quest for health and enable them to improve and maintain their health to the highest level possible, while educating them about the benefits of Chiropractic, Natural Healthcare and Holistic Living, so they in turn can teach others to support us having a healthy community.

Your Choice

• Continue doing the same thing and nothing changes or it may get worse

OR

• Try something different and get a different result that makes you happier and healthier.